54 related articles for article (PubMed ID: 35310605)
1. Identification of the prognostic value of LACTB2 and its correlation with immune infiltrates in ovarian cancer by integrated bioinformatics analyses.
Cao W; Wang C; Zhang Y; Yang J; Luo X; Zhao Y; Wu M; Cheng S; Wang Y
Eur J Med Res; 2024 Mar; 29(1):166. PubMed ID: 38475882
[TBL] [Abstract][Full Text] [Related]
2. Lysophosphatidic acid down-regulates human RIPK4 mRNA in keratinocyte- derived cell lines.
Xu L; Bajorski P; Poligone B
PLoS One; 2024; 19(4):e0287444. PubMed ID: 38630705
[TBL] [Abstract][Full Text] [Related]
3. Author Correction: Comprehensive analysis of TLX2 in pan cancer as a prognostic and immunologic biomarker and validation in ovarian cancer.
Chen B; Ding X; Wan A; Qi X; Lin X; Wang H; Mu W; Wang G; Zheng J
Sci Rep; 2023 Oct; 13(1):17678. PubMed ID: 37848550
[No Abstract] [Full Text] [Related]
4. Exploring the prognostic significance of arm-level copy number alterations in triple-negative breast cancer.
Doré S; Ali M; Sorin M; McDowell SAC; Desharnais L; Breton V; Yu MW; Arabzadeh A; Ryan MI; Milette S; Quail DF; Walsh LA
Oncogene; 2024 May; ():. PubMed ID: 38744952
[TBL] [Abstract][Full Text] [Related]
5. GSK3β and UCHL3 govern RIPK4 homeostasis via deubiquitination to enhance tumor metastasis in ovarian cancer.
Shan W; Peng W; Chen Y; Wang Y; Yu Q; Tian Y; Dou Y; Tu J; Huang X; Li X; Wang Z; Zhu Q; Chen J; Xia B
Oncogene; 2024 Apr; ():. PubMed ID: 38664501
[TBL] [Abstract][Full Text] [Related]
6. Low FHL1 expression indicates a good prognosis and drug sensitivity in ovarian cancer.
Chen X; Yu Y; Su Y; Shi L; Xie S; Hong Y; Liu X; Yin F
Funct Integr Genomics; 2024 Feb; 24(1):25. PubMed ID: 38324167
[TBL] [Abstract][Full Text] [Related]
7. Receptor-interacting protein kinase 2 is associated with tumor immune infiltration, immunotherapy-related biomarkers, and affects gastric cancer cells growth
Yang Q; Hong K; Li Y; Shi P; Yan F; Zhang P
J Cancer; 2024; 15(1):176-191. PubMed ID: 38164277
[No Abstract] [Full Text] [Related]
8. Overexpression of RIPK4 Predicts Poor Prognosis and Promotes Metastasis in Ovarian Cancer.
Liu S; He L; Sheng C; Su R; Wu X; Sun Y; Xi X
Biomed Res Int; 2021; 2021():6622439. PubMed ID: 34124253
[TBL] [Abstract][Full Text] [Related]
9. An Integrative Analysis Revealing ZFHX4-AS1 as a Novel Prognostic Biomarker Correlated with Immune Infiltrates in Ovarian Cancer.
Huang C; Cui H; Lang X; Zhao F
J Immunol Res; 2022; 2022():9912732. PubMed ID: 35795530
[TBL] [Abstract][Full Text] [Related]
10. RIPK4 Is an Immune Regulating-Associated Biomarker for Ovarian Cancer and Possesses Generalization Value in Pan-Cancer.
Liao C; Zhao YX; Han WD; Lai NY
J Immunol Res; 2022; 2022():7599098. PubMed ID: 35310605
[TBL] [Abstract][Full Text] [Related]
11. RIPK4 Promotes Cell Invasion and the Epithelial-Mesenchymal Transition in Ovarian Cancer.
Hua L; Wu JH; Xu JY; Wu SG; Zhou J
Front Biosci (Landmark Ed); 2023 Dec; 28(12):368. PubMed ID: 38179758
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of RIPK4 Expression Inhibits Epithelial-Mesenchymal Transition in Ovarian Cancer through IL-6.
Yi H; Su YZ; Lin R; Zheng XQ; Pan D; Lin DM; Gao X; Zhang R
J Immunol Res; 2021; 2021():8875450. PubMed ID: 33855091
[TBL] [Abstract][Full Text] [Related]
13. Receptor interacting protein kinase 4 promotes cell proliferation, migration, and invasion in ovarian cancer via targeting protein kinase C delta.
Jin A; Zhang L; Fang G; Chen Y
Drug Dev Res; 2022 Apr; 83(2):407-415. PubMed ID: 34414590
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
